{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-032770","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.023166+00:00","generated_at":"2026-05-30T07:27:26.196022+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Pulse Biosciences: nano-PFA reduces benign thyroid nodule volume >50% in feasibility study","bullets":["First-in-human study (30 patients) shows ≥50% nodule volume reduction and symptomatic relief within 1 month.","Results presented at 2024 American Thyroid Association Annual Meeting by PI Dr. Stefano Spiezia.","No residual fibrosis or scarring observed; potential advantage over thermal ablation and surgery.","Company plans to commence pivotal trial mid-2025 to support U.S. labeling indication.","Study NCT06117085 fully enrolled; long-term follow-up ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-032770","json":"https://secwatch.observer/filing/0001437749-24-032770.json","markdown":"https://secwatch.observer/filing/0001437749-24-032770.md","text":"https://secwatch.observer/filing/0001437749-24-032770.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774924032770/0001437749-24-032770-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774924032770/plse20241031c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:27:26.196022+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}